Researchers say gene-based treatments for alcoholism and depression are possible.
Researchers have discovered a pair of genetic mechanisms that could hold the keys to gene therapies for alcoholism and depression.
Scientists at the University of North Carolina, led by Dr. Kirk Wilhelmsen, reported in the journal Alcoholism: Clinical & Experimental Research the discovery of a gene that influences individuals' responses to alcohol. The variant causes a high sensitivity to alcohol in its carriers. Research has shown that others have a much lower sensitivity to the effects of alcohol, which carries a higher risk for alcoholism (people who get tipsy more easily are, conversely, less likely to develop alcoholism).
The gene encodes an enzyme for alcohol metabolization in the brain, rather than the liver as with other alcohol metabolization enzymes. The gene could be useful in determining the likelihood of developing alcoholism.
"Alcoholism is a very complex disease and there are lots of complicated reasons why people drink," Wilhelmsen cautioned in prepared remarks. "This may be just one of the reasons."
In another study, researchers led by Dr. Michael Kaplitt of the Weill Cornell Medical College in New York City discovered that low levels of a protein could help cause depression. The researchers, who included Nobel Prize-winning brain cell researcher Paul Greengard of New York's Rockefeller University, looked to cure mice bred for depressive symptoms by installing a gene carrying the protein into reward center of the brain. The study, in the journal Science Translational Medicine, showed that the gene-treated mice lost their listlessness and behaved like regular mice.
depressed people display a deficit of the protein. Combined with an existing technique for gene therapy, the results suggest a new way to treat depression, as well as a new target for drugs, Kaplitt concludes.
"No single thing probably causes any human disease," Kaplitt told USA Today. "But we can say there is evidence here of a role of this protein in depression."
Terumo strikes a deal with Olympus for its GlideWire urology device, 2 years after spiking a similar...
Tandem Diabetes is taking orders for its new t:flex insulin pump, 4 months after FDA officials...
Iceland's Össur develops bionic implants that allow amputees to control prosthetic limbs with their...
Biolase lures Zimmer Dental president Harold Flynn to be its new CEO.